Retirement Guys Formula LLC Takes $1.15 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Retirement Guys Formula LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,193 shares of the biopharmaceutical company’s stock, valued at approximately $1,148,000.

Several other institutional investors and hedge funds also recently made changes to their positions in REGN. West Paces Advisors Inc. grew its position in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the last quarter. Fortitude Family Office LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $31,000. MCF Advisors LLC grew its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares in the last quarter. Criterion Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $37,000. Finally, Bruce G. Allen Investments LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $40,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.0 %

NASDAQ REGN traded down $20.57 on Thursday, reaching $1,024.09. The company had a trading volume of 378,341 shares, compared to its average volume of 459,242. The firm has a market cap of $112.84 billion, a price-to-earnings ratio of 30.25, a P/E/G ratio of 2.16 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $688.52 and a fifty-two week high of $1,081.17. The business has a 50 day moving average of $992.50 and a two-hundred day moving average of $954.60. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The company had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at $399,729,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the sale, the executive vice president now owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The disclosure for this sale can be found here. Insiders sold 63,208 shares of company stock worth $62,514,142 over the last three months. Company insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on REGN shares. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. UBS Group increased their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Cantor Fitzgerald restated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. Finally, Argus upped their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $1,027.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.